Logo

PCLS, Genesys Partner to Offer Proteomics Lung Cancer Test

Nov 15, 2013 | staff reporter

NEW YORK (GenomeWeb News) – Physician's Choice Laboratory Services today announced a partnership to offer Genesys Biolabs' proteomic test for screening and the early detection of lung cancer.

The test, called PAULA's Test, short for Protein Assay Using Lung Cancer Analytes, measures three tumor proteins and an additional analyte that are commonly associated with lung cancer. The blood-based test is analyzed in Genesys' CLIA-certified laboratory.

Citing statistics from the American Cancer Society, PCLS said that about 228,190 new cases of lung cancer will be diagnosed this year in the US with 159,480 lung cancer-associated deaths.

PCLS, based in Rock Hill, SC, provides toxicology and genetics testing services. Genesys is a division of 20/20 GeneSystems and develops proteomic-based diagnostics tests with a focus on cancer. It is headquartered in Rockville, Md.

Financial and other terms of the agreement were not disclosed.

Filed under

Proteomics & Protein Research
Cancer
Lung Cancer
proteomics
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.